Rationale for the Use of Cyclophosphamide in COVID 19-Associated Pulmonary Fibrosis

Pneumonia is a serious complication of the new coronavirus infection, also known as COVID-19. Patients if risk groups who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. This review analyzes the use of cytostatic agents such as cyclophosphamide with his proven efficacy against lung fibrosis of various etiologies and considers its potential effectiveness in the treatment of post-Covid pulmonary fibrosis.

Authors
Mikaelyan K.A. 1, 4 , Tsarenko S.V.4, 2 , Petrova M.V. 1, 3 , Davydova L.A.4, 2 , Filimonova E.V.4, 2 , Andreev A.A. 2 , Etnyukov E.V.4, 2
Number of issue
S
Language
English
Pages
183-188
Status
Published
Volume
41
Year
2022
Organizations
  • 1 Russian Peoples' Friendship University
  • 2 Moscow City Clinical Hospital 52
  • 3 Lomonosov Moscow State University
  • 4 Federal Research Clinical Center of Intensive Care and Rehabilitation
Date of creation
28.12.2023
Date of change
28.12.2023
Short link
https://repository.rudn.ru/en/records/article/record/99707/
Share

Other records

Вилковыский И.Ф., Ватников Ю.А., Ягников С.А., Шпиньков Д.В., Руснак И.А.
Вестник Красноярского государственного аграрного университета. Федеральное государственное бюджетное образовательное учреждение высшего образования "Красноярский государственный аграрный университет". 2022. P. 161-167